top of page

Rafarma Pharmaceuticals has entered into negotiations with the Institute of Isotopes Co. Ltd.

Rafarma Pharmaceuticals, Inc. (OTC: RAFA), BEBIG and the Institute of Isotopes Co. Ltd. have held a meeting in Budapest and discussed possible options for mutual work, in particular the creation of a full-cycle contract manufacturing (irradiation and packaging) and a partial cycle (packaging) and interest in joint work on the registration of microspheres in the EU.

The key issues at the meeting were the determination of irradiation and packaging cost as of the first quarter of 2022 and preparation for non-radioactive microspheres comparative exposure.

Companies for which this cooperation is not the first also discussed other issues and industry opportunities related to the contract manufacturing of radiopharmaceuticals. Bebig, which will soon become part of the Rafarma Pharmaceuticals group of companies, has long seen prospects in partnership with the Institute of Isotopes Co. Ltd. The production capabilities of the Institute of Isotopes LLC were investigated by a technological audit and analyzed by Bebig in 2020. Unfortunately, the onset of the coronavirus pandemic has significantly slowed down the begun work.

The objective of the current negotiations was to determine the feasibility of replicating Bebig’s most auspicious technologies on the company premises in Budapest. To date, the companies are ready to continue their joint pharmaceutical activities and believe in success despite external circumstances.


Institute of Isotopes Co. Ltd. is on the frontline of radioisotope technology collaborating with long-term partners and customers. The company is dealing with the research, development and production of a wide variety of radioactive isotopes and other products for a broad range of application areas, especially healthcare, research and industry. Over the years the company has developed numerous products from diagnostic kits to radioactive sources for various radioactive applications.

For more information, please visit


Bebig, which will soon become part of the Rafarma Pharmaceuticals group of companies, has been introducing innovative treatment methods of oncological diseases to the Easter Europe market since 2004. For a long time, the company has been focusing on prostate cancer therapy with low-dose iodine-125 brachytherapy. Thus, in 2014, Bebig launched the first plant in Eastern Europe for iodine-125 micro sources production under the license of Eckert & Ziegler, a leading German manufacturer of medical devices and equipment for brachytherapy.

For more information, please visit


Rafarma Pharmaceuticals is an international holding company is engaged in projects conducting the production and market entry of innovative drugs and technology platforms. The business has had a reputation as a reliable manufacturer and distributor since 1930. Rafarma pharmaceuticals run more than 25 programs in molecular biology, nuclear medicine, immunology, sustainable packaging and many other fields at the moment.

For more information, please visit


Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.



(307) 429-2029


7 (495) 780-92-68 / 69


(361) 391-0802

Source: Rafarma Pharmaceuticals, Inc.


bottom of page